Fiscal Year Ending November 2026 Q3 Financial Summary [Japanese GAAP] (Consolidated)

Overview of Results

In this Q3 consolidated financial summary, net sales were 32,293 million yen, up 21.0% year-over-year. Operating income was 7,578.8 million yen, ordinary income was 7,893.688 million yen, and net income attributable to owners of parent for the quarter was 5,325.905 million yen, each significantly exceeding prior-year results. By segment, petrochemicals, electronic materials, and specialty chemicals all showed steady sales and profit performance. Under the medium-term plan "Progress & Development 2030," the company continues capital investment projects for semiconductor materials and is strengthening overseas expansion. Significant changes during the cumulative Q3 period include the addition of Visnex Chemicals Corporation to the scope of consolidation and the commencement of equity-method application for Sanpo Chemical Laboratory.

Outlook and Dividends

The company has revised previously announced earnings guidance and updated forward-looking estimates based on the latest disclosed information. Please refer to the separate "Notice Regarding Revision of Earnings Forecast and Dividend Forecast" for details on full-year projections and dividend revisions for the fiscal year ending November 2026. New capital investment plans to meet growing demand for semiconductor materials are underway; the Sakata plant investment is scheduled to start construction in 2027 and be completed in 2029, with the investment amount increased to approx. 20,000 million yen (reason for change: rise in construction material prices and updated demand estimates).